1.87BMarket Cap
LossP/E TTM
Key Figures
14.500Open
14.530High
159.42KVolume
LossP/E TTM
190.12P/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
14.550Prev. Close
14.045Low
1.45MTurnover
LossP/E Static
3.04P/B
0.00%Div Yield TTM
-14.05%ROA
21.50052wk High
0.71Volume Ratio
-102.14MNet Profit
127.99MShares
-0.8457EPS TTM
2.06Beta
-18.95%ROE
9.88052wk Low
3.33%Amplitude
70.17%Gross Margin
1.87BMarket Cap
0.77Reward/Risk
1.99%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Mesoblast Ltd's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 123 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.67.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Mesoblast Ltd Highlights
StrengthsRisks
Mesoblast Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mesoblast Ltd Info
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Ticker SymbolMESO
CompanyMesoblast Ltd
CEOItescu (Silviu)
Websitehttps://www.mesoblast.com/
Shareholders
FAQs
What is the current price of Mesoblast Ltd (MESO)?
The current price of Mesoblast Ltd (MESO) is 14.17.
What is the symbol of Mesoblast Ltd?
The ticker symbol of Mesoblast Ltd is MESO.
What is the 52-week high of Mesoblast Ltd?
The 52-week high of Mesoblast Ltd is 21.50.
What is the 52-week low of Mesoblast Ltd?
The 52-week low of Mesoblast Ltd is 9.88.
What is the market capitalization of Mesoblast Ltd?
The market capitalization of Mesoblast Ltd is 1.81B.
Is Mesoblast Ltd (MESO) currently rated as Buy, Hold, or Sell?
According to analysts, Mesoblast Ltd (MESO) has an overall rating of Buy, with a price target of 34.67.
What is the Earnings Per Share (EPS TTM) of Mesoblast Ltd (MESO)?
The Earnings Per Share (EPS TTM) of Mesoblast Ltd (MESO) is -0.85.
